Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Bortezomib
Related studies linked through entity extraction aliases.
Bortezomib in Treating Patients With Metastatic Kidney Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Study of Velcade and Thalidomide in Patients With Myelodysplasia
- Status
- TERMINATED
- Phase
- PHASE1
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Bortezomib in Treating Patients With Myelodysplastic Syndromes
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
- Status
- COMPLETED
- Phase
- PHASE4
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2